How to replace the lost keys? Strategies toward safer KV7 channel openers.

The highly structurally similar drugs flupirtine and retigabine have been regarded as safe and effective for many years but lately they turned out to exert intolerable side effects. While the twin molecules share the mode of action, both stabilize the open state of voltage-gated potassium channels, the form and severity of adverse effects is different. The analgesic flupirtine caused drug-induced liver injury in rare but fatal cases, whereas prolonged use of the antiepileptic retigabine led to blue tissue discoloration. Because the adverse effects seem unrelated to the mode of action, it is likely, that both drugs that occupied important therapeutic niches, could be replaced. Reasons for the clinically relevant toxicity will be clarified and future substitutes for these drugs presented in this review.

[1]  Sun Choi,et al.  Promiscuous gating modifiers target the voltage sensor of Kv7.2, TRPV1, and Hv1 cation channels , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Ghanshyam Yadav,et al.  Role of flupirtine in reducing preoperative anxiety of patients undergoing craniotomy procedure , 2017, Saudi journal of anaesthesia.

[3]  B. Terhaag,et al.  Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial* , 2008, Current medical research and opinion.

[4]  Maurizio Taglialatela,et al.  Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites. , 2017, Current medicinal chemistry.

[5]  C. Bundgaard,et al.  Antipsychotic-Like Effect of Retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic Acid Ester], a KCNQ Potassium Channel Opener, via Modulation of Mesolimbic Dopaminergic Neurotransmission , 2009, Journal of Pharmacology and Experimental Therapeutics.

[6]  R. Bergman,et al.  Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. , 2014, JAMA dermatology.

[7]  C. Elger,et al.  Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy , 2010, Neurology.

[8]  H. Husum,et al.  Effect of the new antiepileptic drug retigabine in a rodent model of mania , 2008, Epilepsy & Behavior.

[9]  Jose A. Lopez-Garcia,et al.  Effects of novel subtype selective M-current activators on spinal reflexes in vitro: Comparison with retigabine , 2016, Neuropharmacology.

[10]  Julian Solway,et al.  Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[11]  R. Leroy,et al.  Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy , 2011, Neurology.

[12]  Angel Lanas,et al.  We Are Using Too Many PPIs, and We Need to Stop: A European Perspective , 2016, The American Journal of Gastroenterology.

[13]  Robert H. Brown,et al.  Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. , 2014, Cell reports.

[14]  Thomas Berg,et al.  N‐acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[15]  B S Brown,et al.  KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. , 1998, Science.

[16]  James O McNamara,et al.  In Vivo Profile of ICA-27243 [N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a Potent and Selective KCNQ2/Q3 (Kv7.2/Kv7.3) Activator in Rodent Anticonvulsant Models , 2008, Journal of Pharmacology and Experimental Therapeutics.

[17]  Mario Giorgi,et al.  Synergistic interaction between tapentadol and flupirtine in the rat orafacial formalin test. , 2015, European journal of pharmacology.

[18]  Edeltraut Garbe,et al.  Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. , 2015, British journal of clinical pharmacology.

[19]  Zhen Liu,et al.  KCNQ2/3/5 channels in dorsal root ganglion neurons can be therapeutic targets of neuropathic pain in diabetic rats , 2018, Molecular pain.

[20]  Anastasios V Tzingounis,et al.  Potent KCNQ2/3-Specific Channel Activator Suppresses In Vivo Epileptic Activity and Prevents the Development of Tinnitus , 2015, The Journal of Neuroscience.

[21]  C. Grunwald,et al.  Metabolism of retigabine (D-23129), a novel anticonvulsant. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Paul C Trippier,et al.  Discovery of Aromatic Carbamates that Confer Neuroprotective Activity by Enhancing Autophagy and Inducing the Anti-Apoptotic Protein B-Cell Lymphoma 2 (Bcl-2). , 2017, Journal of medicinal chemistry.

[23]  Robert W. Williams,et al.  Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking. , 2017, Alcohol.

[24]  Bernd Terhaag,et al.  Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study , 2012, Current medical research and opinion.

[25]  Stephanie D Nichols,et al.  A New Tool to Tackle the Opioid Epidemic: Description, Utility, and Results from the Maine Diversion Alert Program , 2017, Pharmacotherapy.

[26]  Andreas Link,et al.  Oxidation Potentials of N‐Modified Derivatives of the Analgesic Flupirtine Linked to Potassium KV7 Channel Opening Activity But Not Hepatocyte Toxicity , 2015, ChemMedChem.

[27]  Takashi Okada,et al.  MicroRNA cluster miR-17-92 regulates multiple functionally related voltage-gated potassium channels in chronic neuropathic pain , 2017, Nature Communications.

[28]  Michal Douša,et al.  Identification, characterization, synthesis and HPLC quantification of new process-related impurities and degradation products in retigabine. , 2014, Journal of pharmaceutical and biomedical analysis.

[29]  John Malysz,et al.  Molecular Expression and Pharmacological Evidence for a Functional Role of Kv7 Channel Subtypes in Guinea Pig Urinary Bladder Smooth Muscle , 2013, PloS one.

[30]  Karen Methling,et al.  Quantitative LC-MS/MS determination of flupirtine, its N-acetylated and two mercapturic acid derivatives in man. , 2015, Journal of pharmaceutical and biomedical analysis.

[31]  D. Strøbæk,et al.  Anxiolytic Effects of Maxipost (BMS-204352) and Retigabine via Activation of Neuronal Kv7 Channels , 2005, Journal of Pharmacology and Experimental Therapeutics.

[32]  Shinichi Hirose,et al.  Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations , 2016, PloS one.

[33]  Jaideep Kapur,et al.  Flupirtine and diazepam combination terminates established status epilepticus: results in three rodent models , 2017, Annals of clinical and translational neurology.

[34]  Qi Gao,et al.  Synthesis and KCNQ2 opener activity of N-(1-benzo[1,3]dioxol-5-yl-ethyl, N-[1-(2,3-dihydro-benzofuran-5-yl)-ethyl, and N-[1-(2,3-dihydro-1H-indol-5-yl)-ethyl acrylamides. , 2004, Bioorganic & medicinal chemistry letters.

[35]  Stefan Boehm,et al.  δ Subunit‐containing GABAA receptors are preferred targets for the centrally acting analgesic flupirtine , 2015, British journal of pharmacology.

[36]  Y Shweikh,et al.  Activation of KV7 channels stimulates vasodilatation of human placental chorionic plate arteries. , 2015, Placenta.

[37]  Eric Marsh,et al.  KCNQ2 encephalopathy , 2016, Neurology: Genetics.

[38]  L. Rønn,et al.  Kv 7 positive modulators reduce detrusor overactivity and increase bladder capacity in rats. , 2012, Basic & clinical pharmacology & toxicology.

[39]  Guang-Di Chen,et al.  Potassium ion channel openers, Maxipost and Retigabine, protect against peripheral salicylate ototoxicity in rats , 2015, Hearing Research.

[40]  Yasunori Sato,et al.  Markedly reduced axonal potassium channel expression in human sporadic amyotrophic lateral sclerosis: An immunohistochemical study , 2011, Experimental Neurology.

[41]  Palle Christophersen,et al.  Characterization of a novel high-potency positive modulator of K(v)7 channels. , 2013, European journal of pharmacology.

[42]  Stefan Boehm,et al.  Concomitant facilitation of GABAA receptors and KV7 channels by the non‐opioid analgesic flupirtine , 2012, British journal of pharmacology.

[43]  Haixia Gao,et al.  Intracellular zinc activates KCNQ channels by reducing their dependence on phosphatidylinositol 4,5-bisphosphate , 2017, Proceedings of the National Academy of Sciences.

[44]  Yuji Ikegaya,et al.  Heterogeneous effects of antiepileptic drugs in an in vitro epilepsy model – a functional multineuron calcium imaging study , 2015, The European journal of neuroscience.

[45]  Andreas Link,et al.  Synthesis and potassium KV7 channel opening activity of thioether analogues of the analgesic flupirtine. , 2018, Organic & biomolecular chemistry.

[46]  Geoffrey W. Abbott,et al.  Direct neurotransmitter activation of voltage-gated potassium channels , 2018, Nature Communications.

[47]  Juan Ren,et al.  Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain. , 2015, Oncology reports.

[48]  Ming Zhou,et al.  Centipedes subdue giant prey by blocking KCNQ channels , 2018, Proceedings of the National Academy of Sciences.

[49]  C. Petit,et al.  KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Vincent Seutin,et al.  Kv7 channels: interaction with dopaminergic and serotonergic neurotransmission in the CNS , 2008, The Journal of physiology.

[51]  Scott M. Rawls,et al.  KCNQ2/3 channel agonist flupirtine reduces cocaine place preference in rats , 2017, Behavioural pharmacology.

[52]  Holger Lerche,et al.  KV7 channelopathies , 2010, Pflügers Archiv - European Journal of Physiology.

[53]  Piotr Radziszewski,et al.  Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years. , 2012, British journal of clinical pharmacology.

[54]  A. Wickenden,et al.  The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site , 2009, Neuroscience Letters.

[55]  G. Landes,et al.  Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias , 1996, Nature Genetics.

[56]  S. H. Hussaini,et al.  Idiosyncratic drug-induced liver injury: an overview , 2007, Expert opinion on drug safety.

[57]  Qing Yang,et al.  Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury. , 2017, Journal of neurotrauma.

[58]  Kenneth L Byron,et al.  Novel treatment strategies for smooth muscle disorders: Targeting Kv7 potassium channels. , 2016, Pharmacology & therapeutics.

[59]  Thanos Tzounopoulos,et al.  Noise-induced plasticity of KCNQ2/3 and HCN channels underlies vulnerability and resilience to tinnitus , 2015, eLife.

[60]  Elissa J Chesler,et al.  Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption , 2016, Addiction biology.

[61]  Fan Zhang,et al.  Activation of KCNQ2/3 Potassium Channels by Novel Pyrazolo[1,5-a]pyrimidin-7(4H)-One Derivatives , 2011, Pharmacology.

[62]  Lal D. Mishra,et al.  Evaluating the Role of Flupirtine for Postcraniotomy Pain and Compare it With Diclofenac Sodium: A Prospective, Randomized, Double Blind, Placebo-controlled Study , 2014, Journal of neurosurgical anesthesiology.

[63]  Meng Cui,et al.  Ca2+-Calmodulin and PIP2 interactions at the proximal C-terminus of Kv7 channels , 2017, Channels.

[64]  Mathias Bähr,et al.  The indirect NMDAR inhibitor flupirtine induces sustained post-ischemic recovery, neuroprotection and angioneurogenesis , 2015, Oncotarget.

[65]  T. Tzounopoulos,et al.  Pathogenic plasticity of Kv7.2/3 channel activity is essential for the induction of tinnitus , 2013, Proceedings of the National Academy of Sciences.

[66]  D. A. Brown,et al.  Activation of Expressed KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents by the Anti-Convulsant Drug Retigabine , 2001, The Journal of Neuroscience.

[67]  B. Attali,et al.  Meclofenamic Acid and Diclofenac, Novel Templates of KCNQ2/Q3 Potassium Channel Openers, Depress Cortical Neuron Activity and Exhibit Anticonvulsant Properties , 2005, Molecular Pharmacology.

[68]  P. Delmas,et al.  Pathways modulating neural KCNQ/M (Kv7) potassium channels , 2005, Nature Reviews Neuroscience.

[69]  Nicole Schmitt,et al.  The acrylamide (S)-1 differentially affects Kv7 (KCNQ) potassium channels , 2006, Neuropharmacology.

[70]  Thomas Friedrich,et al.  Refinement of the Binding Site and Mode of Action of the Anticonvulsant Retigabine on KCNQ K+ Channels , 2009, Molecular Pharmacology.

[71]  Dean P. Jones,et al.  Extracellular redox state: refining the definition of oxidative stress in aging. , 2006, Rejuvenation research.

[72]  Martin J. Brodie,et al.  A case report: retigabine induced oral mucosal dyspigmentation of the hard palate , 2015, BMC oral health.

[73]  Ming-Hu Han,et al.  KCNQ channel openers reverse depressive symptoms via an active resilience mechanism , 2016, Nature Communications.

[74]  M. Nelson,et al.  HLA-DRB1*16: 01-DQB1*05 02 is a novel genetic risk factor for flupirtine-induced liver injury , 2016, Pharmacogenetics and genomics.

[75]  Jürgen Borlak,et al.  Pathology of flupirtine-induced liver injury: , 2011, Virchows Archiv.

[76]  Sarah L. Clark,et al.  New antiepileptic medication linked to blue discoloration of the skin and eyes , 2015, Therapeutic advances in drug safety.

[77]  J Robbins,et al.  KCNQ potassium channels: physiology, pathophysiology, and pharmacology. , 2001, Pharmacology & therapeutics.

[78]  D. Oliver,et al.  Restoration of ion channel function in deafness‐causing KCNQ4 mutants by synthetic channel openers , 2012, British journal of pharmacology.

[79]  Karen Methling,et al.  Metabolic activation and analgesic effect of flupirtine in healthy subjects, influence of the polymorphic NAT2, UGT1A1 and GSTP1. , 2015, British journal of clinical pharmacology.

[80]  Majid Sheykhzade,et al.  Bladder contractility is modulated by Kv7 channels in pig detrusor. , 2013, European journal of pharmacology.

[81]  P H Van de Heyning,et al.  The use of flupirtine in treatment of tinnitus , 2006, Acta oto-laryngologica. Supplementum.

[82]  Ulises Meza,et al.  Regulation of Kv7.2/Kv7.3 channels by cholesterol: Relevance of an optimum plasma membrane cholesterol content. , 2018, Biochimica et biophysica acta. Biomembranes.

[83]  Pingkai Ouyang,et al.  Design, synthesis and evaluation of substituted piperidine based KCNQ openers as novel antiepileptic agents. , 2018, Bioorganic & medicinal chemistry letters.

[84]  András Varró,et al.  Slow Delayed Rectifier Potassium Current (IKs) and the Repolarization Reserve , 2007, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[85]  Mauricio Montal,et al.  The Sensorless Pore Module of Voltage-gated K+ Channel Family 7 Embodies the Target Site for the Anticonvulsant Retigabine* , 2015, The Journal of Biological Chemistry.

[86]  I. Szelenyi,et al.  Flupirtine, a re-discovered drug, revisited , 2013, Inflammation Research.

[87]  R. Wörz,et al.  Zur Langzeitbehandlung chronischer Schmerzpatienten mit Flupirtin , 2014, MMW - Fortschritte der Medizin.

[88]  C. Mancuso,et al.  KV7 channels in the human detrusor: channel modulator effects and gene and protein expression , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

[89]  M. Bal,et al.  Homomeric and Heteromeric Assembly of KCNQ (Kv7) K+ Channels Assayed by Total Internal Reflection Fluorescence/Fluorescence Resonance Energy Transfer and Patch Clamp Analysis* , 2008, Journal of Biological Chemistry.

[90]  Min Li,et al.  Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants. , 2007, Nature chemical biology.

[91]  R. Kass,et al.  KCNE1 and KCNE3 modulate KCNQ1 channels by affecting different gating transitions , 2017, Proceedings of the National Academy of Sciences.

[92]  Vincent Seutin,et al.  The KCNQ Channel Opener Retigabine Inhibits the Activity of Mesencephalic Dopaminergic Systems of the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[93]  J. Borlak,et al.  Correlation versus Causation? Pharmacovigilance of the Analgesic Flupirtine Exemplifies the Need for Refined Spontaneous ADR Reporting , 2011, PloS one.

[94]  Qing Lu,et al.  Flupirtine attenuates chronic restraint stress-induced cognitive deficits and hippocampal apoptosis in male mice , 2015, Behavioural Brain Research.

[95]  Lei Zhang,et al.  Discovery of a novel Kv7 channel opener as a treatment for epilepsy. , 2015, Bioorganic & medicinal chemistry letters.

[96]  W. Alves,et al.  Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures , 2007, Neurology.

[97]  Jai Karan,et al.  A PROSPECTIVE RANDOMIZED COMPARATIVE EVALUATION OF FLUPIRTINE AND DICLOFENAC SODIUM IN POST INGUINAL HERNIA SURGERY PAIN , 2016 .

[98]  B. Abou-Khalil,et al.  Ezogabine skin discoloration is reversible after discontinuation , 2017, Epilepsy & Behavior Case Reports.

[99]  Maria Virginia Soldovieri,et al.  Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs. , 2008, Current opinion in pharmacology.

[100]  Fan Zhang,et al.  Activation of neuronal Kv7/KCNQ/M-channels by the opener QO58-lysine and its anti-nociceptive effects on inflammatory pain in rodents , 2016, Acta Pharmacologica Sinica.

[101]  A. Nistri,et al.  Functional up‐regulation of the M‐current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons , 2018, The Journal of physiology.

[102]  Meng Wu,et al.  Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions* , 2010, The Journal of Biological Chemistry.

[103]  O. Povstyan,et al.  Vasorelaxant effects of novel Kv7.4 channel enhancers ML213 and NS15370 , 2014, British journal of pharmacology.

[104]  Daniel L. Minor,et al.  Structural Insight into KCNQ (Kv7) Channel Assembly and Channelopathy , 2007, Neuron.

[105]  Nicole Schmitt,et al.  The Acrylamide (S)-2 As a Positive and Negative Modulator of Kv7 Channels Expressed in Xenopus laevis Oocytes , 2009, PloS one.

[106]  Prem Puri,et al.  Decreased expression of Kv7 channels in Hirchsprung's disease. , 2017, Journal of pediatric surgery.

[107]  Li Li,et al.  Selective targeting of M‐type potassium Kv7.4 channels demonstrates their key role in the regulation of dopaminergic neuronal excitability and depression‐like behaviour , 2017, British journal of pharmacology.

[108]  A. Amoresano,et al.  Subtype-Selective Activation of Kv7 Channels by AaTXKβ(2–64), a Novel Toxin Variant from the Androctonus australis Scorpion Venom , 2013, Molecular Pharmacology.

[109]  Geoffrey W. Abbott,et al.  Ancient and modern anticonvulsants act synergistically in a KCNQ potassium channel binding pocket , 2018, Nature Communications.

[110]  Zhuxi Chen,et al.  The gating charge pathway of an epilepsy-associated potassium channel accommodates chemical ligands , 2013, Cell Research.

[111]  Alice W Wang,et al.  Sequence determinants of subtype‐specific actions of KCNQ channel openers , 2017, The Journal of physiology.

[112]  D. A. Brown,et al.  Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone , 1980, Nature.

[113]  J. Devaux,et al.  Calmodulin orchestrates the heteromeric assembly and the trafficking of KCNQ2/3 (Kv7.2/3) channels in neurons , 2014, Molecular and Cellular Neuroscience.

[114]  Mark J. Suto,et al.  N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. , 2011, ACS medicinal chemistry letters.

[115]  W. A. Wilson,et al.  N-(6-Chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): A Novel, Selective KCNQ2/Q3 Potassium Channel Activator , 2008, Molecular Pharmacology.

[116]  Yasunori Sato,et al.  Motor axonal excitability properties are strong predictors for survival in amyotrophic lateral sclerosis , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[117]  F Zhang,et al.  Modulation of Kv7 potassium channels by a novel opener pyrazolo[1,5‐a]pyrimidin‐7(4H)‐one compound QO‐58 , 2013, British journal of pharmacology.

[118]  Nicole Schmitt,et al.  Differential Effects of ICA-27243 on Cloned KV7 Channels , 2010, Pharmacology.

[119]  A. Brooks-Kayal,et al.  A KCNQ channel opener for experimental neonatal seizures and status epilepticus , 2009, Annals of neurology.

[120]  Qi Gao,et al.  (S)-N-[1-(4-cyclopropylmethyl-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl)-ethyl]-3-(2-fluoro-phenyl)-acrylamide is a potent and efficacious KCNQ2 opener which inhibits induced hyperexcitability of rat hippocampal neurons. , 2004, Bioorganic & medicinal chemistry letters.

[121]  Dominik Irnich,et al.  Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial , 2012, Journal of Translational Medicine.

[122]  G. Seebohm,et al.  Atomic basis for therapeutic activation of neuronal potassium channels , 2015, Nature Communications.

[123]  Lezanne Ooi,et al.  Transcriptional repression of the M channel subunit Kv7.2 in chronic nerve injury , 2011, PAIN®.

[124]  Fan Zhang,et al.  European Journal of Medicinal Chemistry , 2022 .

[125]  X Zhou,et al.  Novel role of KCNQ2/3 channels in regulating neuronal cell viability , 2011, Cell Death and Differentiation.

[126]  Guenter W Gross,et al.  Pharmacodynamics of potassium channel openers in cultured neuronal networks. , 2014, European journal of pharmacology.

[127]  Nicole Schmitt,et al.  From Pan-Reactive KV7 Channel Opener to Subtype Selective Opener/Inhibitor by Addition of a Methyl Group , 2014, PloS one.

[128]  Andrew M. White,et al.  Anticonvulsant effect of flupirtine in an animal model of neonatal hypoxic-ischemic encephalopathy , 2017, Neuropharmacology.

[129]  Manoj Kumar,et al.  Synthesis and Evaluation of Potent KCNQ2/3-Specific Channel Activators , 2016, Molecular Pharmacology.

[130]  J. Mikkelsen,et al.  Retigabine: chemical synthesis to clinical application. , 2006, CNS drug reviews.

[131]  A. Gurney,et al.  Functional expression of KCNQ (Kv7) channels in guinea pig bladder smooth muscle and their contribution to spontaneous activity , 2013, British journal of pharmacology.

[132]  Winfried Schlee,et al.  Potassium channels as promising new targets for pharmacologic treatment of tinnitus: Can Internet-based ‘crowd sensing’ initiated by patients speed up the transition from bench to bedside? , 2016, Expert opinion on therapeutic targets.

[133]  Thomas Friedrich,et al.  A carboxy‐terminal domain determines the subunit specificity of KCNQ K+ channel assembly , 2003, EMBO reports.

[134]  Nir Ben-Tal,et al.  Targeting the voltage sensor of Kv7.2 voltage-gated K+ channels with a new gating-modifier , 2010, Proceedings of the National Academy of Sciences.

[135]  L. Cribbs,et al.  Differential Activation of Vascular Smooth Muscle Kv7.4, Kv7.5, and Kv7.4/7.5 Channels by ML213 and ICA-069673 , 2014, Molecular Pharmacology.

[136]  Haibo Yu,et al.  Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. , 2011, ACS chemical neuroscience.

[137]  Robert Hermann,et al.  N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. , 2006, Metabolism: clinical and experimental.

[138]  B. Attali,et al.  A Tale of Switched Functions: From Cyclooxygenase Inhibition to M-Channel Modulation in New Diphenylamine Derivatives , 2007, PloS one.

[139]  Mark S. Shapiro,et al.  Affinity for phosphatidylinositol 4,5-bisphosphate determines muscarinic agonist sensitivity of Kv7 K+ channels , 2009, The Journal of general physiology.

[140]  Sowmya Chinnaiyan,et al.  A comparative study of efficacy and safety of flupirtine versus piroxicam in postoperative pain in patients undergoing lower limb surgery , 2017, Journal of pain research.

[141]  Karen Methling,et al.  Investigation of the in Vitro Metabolism of the Analgesic Flupirtine , 2009, Drug Metabolism and Disposition.

[142]  Min Li,et al.  Combinatorial augmentation of voltage-gated KCNQ potassium channels by chemical openers , 2008, Proceedings of the National Academy of Sciences.

[143]  Yang Li,et al.  Regulation of Kv7 (KCNQ) K+ Channel Open Probability by Phosphatidylinositol 4,5-Bisphosphate , 2005, The Journal of Neuroscience.

[144]  Edeltraut Garbe,et al.  Erratum to: Flupirtine-induced liver injury—Seven cases from the Berlin Case–control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database , 2015, European Journal of Clinical Pharmacology.

[145]  Holger Lerche,et al.  The New Anticonvulsant Retigabine Favors Voltage-Dependent Opening of the Kv7.2 (KCNQ2) Channel by Binding to Its Activation Gate , 2005, Molecular Pharmacology.

[146]  Laura Micheli,et al.  Effects of natural and synthetic isothiocyanate-based H2S-releasers against chemotherapy-induced neuropathic pain: Role of Kv7 potassium channels , 2017, Neuropharmacology.

[147]  Andrew M. White,et al.  Flupirtine effectively prevents development of acute neonatal seizures in an animal model of global hypoxia , 2015, Neuroscience Letters.